Loading...

Brilliant Violet 711™ anti-mouse/human CD11b Antibody

Pricing & Availability
Clone
M1/70 (See other available formats)
Regulatory Status
RUO
Other Names
αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
M1slash70_BV711_061512
C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 711™. Data shown was gated on the myeloid cell population.
  • M1slash70_BV711_061512
    C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 711™. Data shown was gated on the myeloid cell population.
Compare all formats See Brilliant Violet 711™ spectral data
Cat # Size Price Save
101241 125 µL ¥45,980
101242 50 µg ¥51,730
Description

CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Rabbit
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C57BL/10 splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.4 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1,4, in vitro blocking3,9,12, depletion2,8, immunofluorescence microscopy6,7,10, immunohistochemistry of acetone-fixed frozen sections5,11-13, and spatial biology (IBEX)35,36. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).

Application References

(PubMed link indicates BioLegend citation)
  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  35. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  36. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  2. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed
  3. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  4. Houlder E, et al. 2023. Nat Commun. 14:1863. PubMed
  5. Gressier E, et al. 2023. Nat Immunol. 24:979. PubMed
  6. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  7. Carone M, et al. 2023. Nat Commun. 14:3489. PubMed
  8. Barkaway A, et al. 2021. Immunity. . PubMed
  9. Yamin R, et al. 2021. Nature. 599:465. PubMed
  10. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  11. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  12. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  13. Wang L, et al. 2022. Cell Metab. 34:75. PubMed
  14. Sefik E, et al. 2022. Nature. 606:585. PubMed
  15. Merana GR, et al. 2022. Cell Rep. 39:110891. PubMed
  16. Jang HJ, et al. 2022. Cancer Res. 82:2593. PubMed
  17. Yau E, et al. 2021. Immunobiology. 226:152150. PubMed
  18. Wietecha MS, et al. 2020. Nat Commun. 2.266666667. PubMed
  19. Ancey PB, et al. 2021. Cancer Res. 81:2345. PubMed
  20. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  21. Sharma K, et al. 2021. Cell Reports. 36(3):109351. PubMed
  22. Kim YS, et al. 2021. Cell Death Dis. 12:307. PubMed
  23. Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed
  24. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  25. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  26. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  27. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  28. AR P, et al. 2016. Circ Res. 118: 400-409. PubMed
  29. Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  30. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  31. Nguyen CM, et al. 2019. Diabetes. 68:1499. PubMed
  32. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  33. LaMarche NM, et al. 2020. Cell Metabolism. 32(2):243-258.e6. PubMed
  34. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  35. Ellis G, et al. 2015. EMBO Rep. 16: 1203-1218. PubMed
  36. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  37. Haruna M, et al. 2020. Biol Pharm Bull. 43:399. PubMed
  38. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  39. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  40. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  41. Hossain DMS, et al. 2018. J Clin Invest. 128:644. PubMed
  42. Lim HY et al. 2018. Immunity. 49(2):326-341 . PubMed
  43. Deng M, et al. 2020. Nat Commun. 11:2193. PubMed
  44. Sutherland TE, et al. 2021. Frontiers in Immunology. 12:715209. PubMed
  45. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  46. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  47. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  48. Yankova E, et al. 2021. Nature. 593:597. PubMed
  49. Carter TJ, et al. 2021. Small. 17:e2005241. PubMed
  50. Medler TR et al. 2018. Cancer cell. 34(4):561-578 . PubMed
  51. Pennock ND, et al. 2018. J Immunother Cancer. 0.318055556. PubMed
  52. Sefik E, et al. 2021. Nat Biotechnol. . PubMed
  53. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  54. Kim P, et al. 2015. Infect Immun . 83: 2992 - 3002. PubMed
  55. Goh PK, et al. 2022. Sci Adv. 8:eabk3338. PubMed
  56. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  57. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  58. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  59. Youshani AS, et al. 2019. J Neuroinflammation. 16:25. PubMed
  60. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  61. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  62. Weinstock NI, et al. 2020. Neuron. 107(1):65-81. PubMed
  63. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  64. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  65. Gardner P, et al. 2017. Sci Rep. 7:40830. PubMed
  66. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  67. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  68. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  69. Lee HN, et al. 2022. JCI Insight. 7:. PubMed
  70. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  71. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  72. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  73. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  74. Youssif C, et al. 2018. EMBO Mol Med. 10:e8403. PubMed
  75. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  76. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed
  77. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
RRID
AB_2563310 (BioLegend Cat. No. 101241)
AB_2563310 (BioLegend Cat. No. 101242)

Antigen Details

Structure
Integrin family, associates with integrin β2 (CD18), 170 kD
Distribution

Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells

Function
Adhesion, chemotaxis
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type
B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Coxon A, et al. 1996. Immunity 5:653.

Gene ID
16409 View all products for this Gene ID 3684 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD11b
Specificity Alt (DOES NOT SHOW ON TDS):
CD11b
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD11b on UniProt.org

Other Formats

View All CD11b Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse/human CD11b M1/70 FC
Biotin anti-mouse/human CD11b M1/70 FC
FITC anti-mouse/human CD11b M1/70 FC
PE anti-mouse/human CD11b M1/70 FC,IHC
PE/Cyanine5 anti-mouse/human CD11b M1/70 FC
Purified anti-mouse/human CD11b M1/70 FC,CyTOF®,IP,IHC-F,ICC
PE/Cyanine7 anti-mouse/human CD11b M1/70 FC
Alexa Fluor® 488 anti-mouse/human CD11b M1/70 FC,IHC-F,3D IHC,SB
Alexa Fluor® 647 anti-mouse/human CD11b M1/70 FC,3D IHC,SB
Alexa Fluor® 700 anti-mouse/human CD11b M1/70 FC
Pacific Blue™ anti-mouse/human CD11b M1/70 FC
APC/Cyanine7 anti-mouse/human CD11b M1/70 FC
PerCP/Cyanine5.5 anti-mouse/human CD11b M1/70 FC
PerCP anti-mouse/human CD11b M1/70 FC
Brilliant Violet 421™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 570™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 605™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 650™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 711™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 785™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 510™ anti-mouse/human CD11b M1/70 FC,ICC
Ultra-LEAF™ Purified anti-mouse/human CD11b M1/70 FC,CyTOF®,IP,Block,Depletion,IHC-F,ICC
Purified anti-mouse/human CD11b (Maxpar® Ready) M1/70 FC,CyTOF®
Alexa Fluor® 594 anti-mouse/human CD11b M1/70 IHC-F,FC
PE/Dazzle™ 594 anti-mouse/human CD11b M1/70 FC
APC/Fire™ 750 anti-mouse/human CD11b M1/70 FC
TotalSeq™-A0014 anti-mouse/human CD11b M1/70 PG
Brilliant Violet 750™ anti-mouse/human CD11b M1/70 FC
TotalSeq™-B0014 anti-mouse/human CD11b M1/70 PG
TotalSeq™-C0014 anti-mouse/human CD11b M1/70 PG
Spark NIR™ 685 anti-mouse/human CD11b M1/70 FC
PE/Fire™ 640 anti-mouse/human CD11b M1/70 FC
Spark YG™ 593 anti-mouse/human CD11b M1/70 FC
Spark YG™ 570 anti-mouse/human CD11b M1/70 IHC-F
PE/Fire™ 810 anti-mouse/human CD11b M1/70 FC
APC/Fire™ 810 anti-mouse/human CD11b Antibody M1/70 FC
Spark Blue™ 550 anti-mouse/human CD11b M1/70 FC
Spark UV™ 387 anti-mouse/human CD11b M1/70 FC
PerCP/Fire™ 806 anti-mouse/human CD11b M1/70 FC
PerCP/Fire™ 780 anti-mouse/human CD11b M1/70 FC
Spark Blue™ 574 anti-mouse/human CD11b (Flexi-Fluor™) M1/70 FC
KIRAVIA Blue 520™ anti-mouse/human CD11b M1/70 FC
PE/Fire™ 744 anti-mouse/human CD11b M1/70 FC
Spark PLUS UV395™ anti-mouse/human CD11b M1/70 FC
Spark Red™ 718 anti-mouse/human CD11b (Flexi-Fluor™) M1/70 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account